以下为当前的临床试验。
按院区、状态和其他条件筛选该研究列表。
Rochester, Minn.
The primary aim of this study is to define a comprehensive digital phenotype that predicts risk for near-future relapse or relapse in alcohol use in patients with alcohol-associated liver disease.
The secondary aim of this study is to assess the relationship between this digital phenotype and markers of disease severity outcome, including MELD score and readmission rates.
Rochester, Minn., Albert Lea, Minn.
The purpose of this project is to identify biomarkers by discovery of genomic and metabolomic markers associated with response to acamprosate treatment. To achieve this we will use “pharmacometabolomics-informed pharmacogenomics” such as generation a panel of iPSCs (stem cells) to discover biomarkers. A new prospective randomized placebo-controlled trial of 3 month long treatment with acamprosate/placebo will provide new biospecimens, in addition to previously collected biospecimens, to enable the search for genetic and metabolomic biomarkers associated with sobriety or relapse in participants of this new study.
The purpose of this study is to investigate the effects of buprenorphine on hyperalgesia (HP) perception in adults undergoing treatment for opioid use disorder (OUD).
The purpose of this study is to see if an experimental agent, when given to subjects who wish to abstain from cocaine, will decrease their craving for cocaine and prevent them from relapsing and returning to cocaine use. This experimental agent is called AAV8-hCocH; and it is a gene modified viral vector. We want to determine the safety of its use in adults who have a cocaine use disorder in sustained remission.
The purpose of this study is to investigate the facilitators and barriers of adults with a history of cocaine use disorder (CocUD) in sustained remission to participating in a Phase I gene transfer study aimed at reducing the rate of cocaine relapse.
Albert Lea, Minn., Rochester, Minn.
The purpose of this study is to establish an opioid and multiple addiction (OMA) biobank that creates a comprehensive standard patient phenotype using standardized subjective assessments and objective behavioral measurements for future research.
The purpose of this study is to evaluate the safety, tolerability and effectiveness of V117957, compared to placebo, in subjects with alcohol use disorder (AUD) who experience insomnia associated with alcohol cessation.
您的捐赠可以抵税。请您慷慨解囊,和我们一起进行尖端研究和医护,共同推动医学的改变。